oral WT and F877L mut. AR inhibitor

completed Ph. I/II trial in mCPRC

no hepatotox. vs. bioactivated prior lead

J. Med. Chem., Jan. 20, 2021

Janssen R&D, Spring House, PA

Chemical structure of molecule JNJ-63576253 Androgen Receptor Antagonist

The JNJ AR antagonist, JNJ-63576253, is a clinical molecule for prostate cancer that is active against both wild-type androgen receptor as well as the clinically relevant AR mutant, F877L.…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: